ISPC vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The company is in severe financial distress, evidenced by a critical Piotroski F-Score of 1/9 and a total absence of a viable Altman Z-Score. Revenue has collapsed by 96.50% year-over-year, while operating margins have plummeted to -5192.87%, indicating a complete breakdown of the business model. With a 5-year price decline of 99.9% and a technical trend score of 0/100, the stock is in a terminal bearish phase. Despite a low debt-to-equity ratio, the lack of top-line growth and extreme losses make the equity highly speculative and high-risk.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ISPC vs LLY: Head-to-Head Comparison
This page compares iSpecimen Inc. (ISPC) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.